335 related articles for article (PubMed ID: 30946047)
21. Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension.
Mulvaney EP; Reid HM; Bialesova L; Mendes-Ferreira P; Adão R; Brás-Silva C; Kinsella BT
Eur J Pharmacol; 2020 Dec; 889():173658. PubMed ID: 33121950
[TBL] [Abstract][Full Text] [Related]
22. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
23. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
24. Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry.
Garcia AR; Blanco I; Ramon L; Pérez-Sagredo J; Guerra-Ramos FJ; Martín-Ontiyuelo C; Tura-Ceide O; Pastor-Pérez F; Escribano-Subías P; Barberà JA
Respir Res; 2023 Sep; 24(1):223. PubMed ID: 37715261
[TBL] [Abstract][Full Text] [Related]
25. Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis.
Sakao S; Tanabe N; Tatsumi K
J Am Heart Assoc; 2019 Aug; 8(16):e013310. PubMed ID: 31423872
[No Abstract] [Full Text] [Related]
26. Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat.
Poch DS
BMC Pulm Med; 2016 May; 16(1):82. PubMed ID: 27193179
[TBL] [Abstract][Full Text] [Related]
27. Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Kam CW; Ruiz FE
Pediatr Pulmonol; 2021 Mar; 56(3):593-613. PubMed ID: 33002306
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis.
Buendía JA; Lindarte EF; Guerrero Patiño D
Value Health Reg Issues; 2023 Jul; 36():44-50. PubMed ID: 37028260
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.
Ghofrani HA; Wiedemann R; Rose F; Olschewski H; Schermuly RT; Weissmann N; Seeger W; Grimminger F
Ann Intern Med; 2002 Apr; 136(7):515-22. PubMed ID: 11926786
[TBL] [Abstract][Full Text] [Related]
30. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
[TBL] [Abstract][Full Text] [Related]
31. Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease.
Humpl T; Reyes JT; Erickson S; Armano R; Holtby H; Adatia I
Cardiol Young; 2011 Apr; 21(2):187-93. PubMed ID: 21138617
[TBL] [Abstract][Full Text] [Related]
32. Associations Between Sildenafil Use and Changes in Days of Hospitalization in a Population With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease.
Yang X; Sanders KN; Mardekian J; Mychaskiw MA; Thomas J
Clin Ther; 2015 May; 37(5):1055-63. PubMed ID: 25818118
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Beraprost Sodium Combined with Sildenafil and Its Effects on Vascular Endothelial Function and Inflammation in Patients Experiencing Left Heart Failure Complicated with Pulmonary Arterial Hypertension.
Sun D; Yang W; Wang Z; Gao B
Med Sci Monit; 2021 Feb; 27():e928413. PubMed ID: 33531453
[TBL] [Abstract][Full Text] [Related]
34. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
Channick R; Preston I; Klinger JR
Clin Chest Med; 2013 Dec; 34(4):811-24. PubMed ID: 24267306
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts.
Sabri MR; Bigdelian H; Hosseinzadeh M; Ahmadi A; Ghaderian M; Shoja M
Cardiol Young; 2017 Nov; 27(9):1686-1693. PubMed ID: 28994364
[TBL] [Abstract][Full Text] [Related]
36. Sildenafil in Term and Premature Infants: A Systematic Review.
Perez KM; Laughon M
Clin Ther; 2015 Nov; 37(11):2598-2607.e1. PubMed ID: 26490498
[TBL] [Abstract][Full Text] [Related]
37. Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors.
Kane LB; Klings ES
Treat Respir Med; 2006; 5(4):271-82. PubMed ID: 16808546
[TBL] [Abstract][Full Text] [Related]
38. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
[TBL] [Abstract][Full Text] [Related]
39. Sildenafil for the Treatment of Pulmonary Arterial Hypertension in Infants with Bronchopulmonary Dysplasia.
Trottier-Boucher MN; Lapointe A; Malo J; Fournier A; Raboisson MJ; Martin B; Moussa A
Pediatr Cardiol; 2015 Aug; 36(6):1255-60. PubMed ID: 25824807
[TBL] [Abstract][Full Text] [Related]
40. Advances in the discovery of drugs that treat pulmonary arterial hypertension.
Zolty R
Expert Opin Drug Discov; 2023 Apr; 18(4):445-466. PubMed ID: 37013267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
